Extra-Oral Expression of Bitter T2Rs {#S1}
====================================

*TAS2R*/T2Rs (*gene* and protein) were first discovered within type II taste receptor cells in the tongue and act as sentinels in protecting against the ingestion of potentially toxic substances ([@B23]; [@B107]). Since these pioneering studies, T2R expression has been reported in a multitude of extra-oral tissues, including the gut, lungs, brain, and heart ([@B163]; [@B53]; [@B59]), but their complete function(s) in physiology and pathophysiology remain to be defined. In [Table 1](#T1){ref-type="table"}, we have summarized the location, expression profile and proposed function for the T2R family across a range of human tissues and cells. In regard to function, we would offer a note of caution that a number of studies (listed in [Table 1](#T1){ref-type="table"}) have proposed functions based on stimulation with various bitter compounds in the micromolar to millimolar range where the selectivity and specificity toward T2Rs may reasonably be questioned. Despite this, the expression of T2Rs within the cardiovascular system, particularly the heart and vasculature, has gained significant interest in recent years. Following our initial discovery of *TAS2Rs* within the heart ([@B53]), a number of subsequent studies have focused on the vasculature ([@B109]; [@B114]; [@B187]; [@B24]). An unambiguous definition of their function has, however, lagged behind the capacity to demonstrate their expression.

###### 

Distribution, expression profile, proposed function, and technique used for the detection of extra-oral *TAS2R*/T2R expression.

  **System**         **Cell/tissue**                                                                                                                                                          **TAS2Rs**                                                                                           **Proposed function**                                                                                                **Technique(s) used**                                                                                          **Year**
  ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ----------
  Cardiovascular     Heart                                                                                                                                                                    *TAS2Rs (TAS2R3, 4, 5, 9, 10, 13, 14, 19, 20, 30, 31, 43, 45, 46, 50)*                               Nutrient sensing, contractility                                                                                      RT-qPCR                                                                                                        [@B53]
                     VSMCs                                                                                                                                                                    *TAS2R46, T2R46*                                                                                     Vasodilation                                                                                                         RT-qPCR, IHC, Ca^2+^ imaging                                                                                   [@B109]
                     Artery (pulmonary)                                                                                                                                                       *TAS2Rs (TAS2R3, 4, 10, 14)*                                                                         Vasodilation                                                                                                         PCR                                                                                                            [@B114]
                     Pulmonary VSMCs                                                                                                                                                          *TAS2Rs (TAS2R1, 3, 4, 5, 7, 8, 9, 10, 13, 14, 19, 20, 30, 31, 39, 42, 43, 45, 46, 50, 60*           Vasoconstriction                                                                                                     RT-qPCR                                                                                                        [@B187]
                     Artery (omental)                                                                                                                                                         *TAS2Rs (TAS2R3, 4, 7, 10, 14, 39, 40), T2R7*                                                        Vasodilation                                                                                                         RT-qPCR, WB                                                                                                    [@B24]
                     Venous blood                                                                                                                                                             *TAS2R38*                                                                                            Sensing biofilm formation                                                                                            RT-qPCR                                                                                                        [@B19]
  Endocrine          Adipocyte                                                                                                                                                                *TAS2R46*                                                                                            --                                                                                                                   RT-qPCR                                                                                                        [@B109]
                     Thyroid, Nthy-ori 3-1 cells                                                                                                                                              *TAS2Rs (TAS2R3, 4, 5, 9, 10, 13, 14, 16, 20, 30, 38, 42, 43, 45, 46)*                               Modulation of thyroid hormone production                                                                             RT-qPCR                                                                                                        [@B29]
                     Pancreas (ductal adenocarcinoma biopsy), SU8686 cells, T3M4 cells, MiaPaCa-2 cells, RLT cells                                                                            T2R38                                                                                                Cancer drug resistance, microbiota link to cancer                                                                    Cytofluorometry, WB                                                                                            [@B58]
                     PANC-1 cells, BxPC-3 cells                                                                                                                                               T2R10                                                                                                Cancer drug resistance                                                                                               Flow cytometry                                                                                                 [@B173]
  Gastrointestinal   Colon, Gut HuTu 80 cells, NCI-H716 cells                                                                                                                                 *TAS2Rs (TAS2R3, 4, 5, 10, 13, 20, 30, 31, 38, 39, 40, 42, 43, 45, 46, 50, 60)*                      --                                                                                                                   RT-PCR, Ca^2+^ imaging                                                                                         [@B155]
                     Cecum, NCI-H716 cells                                                                                                                                                    *TAS2R9*                                                                                             Glucose homeostasis                                                                                                  RT-PCR, Ca2^+^ imaging                                                                                         [@B45]
                     Colon                                                                                                                                                                    *TAS2R (TAS2R1, 4, 38)*                                                                              --                                                                                                                   RT-PCR                                                                                                         [@B81]
                     Caco-2 cells                                                                                                                                                             *TAS2R38*                                                                                            Limits absorption of bitter tasting/toxic substances                                                                 RT-PCR, siRNA                                                                                                  [@B79]
                     Saliva                                                                                                                                                                   *TAS2R43*                                                                                            Balkan endemic nephropathy (BEN)                                                                                     RT-PCR                                                                                                         [@B200]
                     HuH7 cells                                                                                                                                                               T2R38                                                                                                --                                                                                                                   Cytofluorometry                                                                                                [@B58]
                     Parotid gland                                                                                                                                                            *TAS2R38*                                                                                            --                                                                                                                   IHC                                                                                                            [@B197]
                     Stomach (epithelial and parietal cells), HGT-1 cells                                                                                                                     *TAS2Rs (TAS2R1, 3, 4, 5, 7, 9, 10, 13, 14, 16, 19, 20, 30, 31, 38, 39, 40, 41, 42, 43, 46, 50)*     Gastric acid secretion                                                                                               RT-PCR                                                                                                         [@B101]
  Integumentary      MDA-MB-231 cells, MCF-7, MCF-10 cells                                                                                                                                    *TAS2R (TAS2R1, 4, 10, 20, 38), T2R38*                                                               --                                                                                                                   qPCR, flow cytometry, Ca^2+^ mobilization                                                                      [@B169]
                     HPKs, HeCaT cells                                                                                                                                                        *TAS2R1, TAS2R38, T2R1, T2R38*                                                                       Keratinocyte differentiation                                                                                         IHC, RT-PCR                                                                                                    [@B197]
                     Skin biopsies with epidermis and dermis                                                                                                                                  *TAS2Rs (TAS2R3, 4, 5, 9, 10, 13, 14, 16, 19, 20, 30, 31, 38, 39, 40, 41, 42, 43, 45, 46, 50, 60)*   --                                                                                                                   qPCR                                                                                                           [@B164]
  Immune             Leukocytes, blood T- and B-lymphocytes, monocytes, neutrophils, NK cells                                                                                                 *TAS2Rs (TAS2R4, 5, 10, 13, 14, 19, 20, 45, 46, 50)*                                                 Anti-inflammatory role in asthma                                                                                     Microarray, RT-qPCR, cytokine ELISA                                                                            [@B136]
                     Core blood-derived mast cells, HMC1.2 cells                                                                                                                              *TAS2Rs (TAS2R3, 4, 5, 10, 13, 14, 19, 20, 46)*                                                      Anti-inflammatory                                                                                                    RT-qPCR                                                                                                        [@B48]
                     Neutrophils, monocytes, HL-60 cells and U937 cells                                                                                                                       T2R38                                                                                                Sensing biofilms                                                                                                     Cytofluorometry and laser scan microscopy                                                                      [@B57]
                     Lymphocytes                                                                                                                                                              T2R38                                                                                                Immune modulation                                                                                                    Flow cytometry                                                                                                 [@B181]
  Skeletomuscular    BMSCs, osteocyte, chondrocyte                                                                                                                                            *TAS2R46, T2R46*                                                                                     Chemosensory                                                                                                         iTRAQ-based mass spectrometry, RT-qPCR, flow cytometry, IHC, Ca^2+^ imaging                                    [@B109]
  Nervous            Frontal cortex                                                                                                                                                           *TAS2Rs (TAS2R5, 10, 13, 50)*                                                                        --                                                                                                                   RT-qPCR, microarray                                                                                            [@B59]
                     Cortex (pyramidal cells), cerebellum (Purkinje cells), hippocampus, SH-SY5Y cells                                                                                        *TAS2R16, T2R16*                                                                                     Neurite growth                                                                                                       IHC, PCR                                                                                                       [@B198]
                     Dorsolateral prefrontal cortex                                                                                                                                           *TAS2Rs (TAS2R4, 5, 10, 13, 14, 50)*                                                                 Cognition                                                                                                            RT-qPCR                                                                                                        [@B4]
                     Purkinje cells                                                                                                                                                           T2R38                                                                                                --                                                                                                                   IHC                                                                                                            [@B197]
                     Neurons/glial cells                                                                                                                                                      T2R38                                                                                                --                                                                                                                   IHC                                                                                                            [@B197]
  Urogenital         Bladder cancer biopsies                                                                                                                                                  *TAS2R1*                                                                                             --                                                                                                                   FISH                                                                                                           [@B214]
                     Testis                                                                                                                                                                   *TAS2Rs (TAS2R14, 16, 38)*                                                                           --                                                                                                                   RT-qPCR                                                                                                        [@B10]
                     HeLa cells, DU145 cells                                                                                                                                                  *TAS2R13*                                                                                            Cytokinesis                                                                                                          RT-PCR, siRNA screen                                                                                           [@B211]
                     SKOV-3 cells                                                                                                                                                             T2R38                                                                                                --                                                                                                                   Cytofluorometry, WB                                                                                            [@B58]
                     Placenta, JEG-3 cells                                                                                                                                                    T2R38                                                                                                --                                                                                                                   IHC, immunofluorescence, restriction enzyme-based detection, Ca^2+^ mobilization                               [@B197]
                     Kidney                                                                                                                                                                   T2R38                                                                                                --                                                                                                                   IHC                                                                                                            [@B197]
                     Cervix                                                                                                                                                                   T2R38                                                                                                --                                                                                                                   IHC                                                                                                            [@B197]
                     Myometrium, hTERT-HM cells                                                                                                                                               *TAS2R (TAS2R5, 10, 13, 14); TAS2R (TAS2R3, 4, 5, 7, 8, 10, 13, 14, 31, 39, 42, 43, 45, 50)*         --                                                                                                                   IHC, Ca^2+^ mobilization, RT-PCR                                                                               [@B213]
                     Sperm                                                                                                                                                                    *TAS2R14, TAS2R43*                                                                                   Sperm motility and maturation                                                                                        Allele-specific PCR                                                                                            [@B61]
                     Ovarian cystadenocarcinoma tumor, uterine tissue, OVCAR4 cells, OVCAR8 cells, SKOV3 cells, IGROV1 cells, HEC-1a cells, BPH1 cells, PC3 cells, LNCAP cells, DU145 cells   *TAS2R (TAS2R1, 4, 10, 14, 38)*                                                                      Cell survival                                                                                                        qPCR, siRNA screen, WB                                                                                         [@B115]
  Respiratory        Bronchial epithelial cells                                                                                                                                               *TAS2Rs (TAS2R1, 3, 4, 7, 8, 9, 10, 13, 14), T2R4, T2R43, T2R46*                                     Motile cilia clearance of inhaled pathogens                                                                          Microarray, RT-PCR, IHC, Ca^2+^ imaging, ciliary beat frequency assay                                          [@B163]
                     ASM, trachea                                                                                                                                                             *TAS2Rs (TAS2R1, 3, 4, 5, 8, 9, 10, 13, 14, 19, 20, 30, 31, 42, 45, 46, 50)*                         Relaxation of isolated ASM, bronchodilation                                                                          RT-qPCR, Ca^2+^ imaging, isolated trachea, single cell mechanics/membrane potentials                           [@B39]
                     16HBE cells                                                                                                                                                              *TAS2R38, TAS2R46*                                                                                   --                                                                                                                   RT-PCR, Ca^2+^ mobilization, cAMP accumulation                                                                 [@B32]
                     Upper respiratory epithelium                                                                                                                                             *TAS2R38, T2R38*                                                                                     NO-mediated increase in ciliary beat frequency/mucous clearance and antibacterial effects in respiratory infection   IHC, Ca^2+^ imaging, NO production, ciliary beat frequency assay, mucous clearance assay, bactericidal assay   [@B96]
                     Nasal epithelial cells                                                                                                                                                   *TAS2R38*                                                                                            Innate immunity                                                                                                      RT-qPCR                                                                                                        [@B96]
                     Solitary or brush chemosensory cells                                                                                                                                     *TAS2R (TAS2R4, 14, 46)*                                                                             Innate immunity                                                                                                      RT-qPCR                                                                                                        [@B8]
                     Bronchi                                                                                                                                                                  *TAS2Rs (TAS2R3, 4, 5, 7, 8, 9, 10, 14, 19, 20, 31, 38, 39, 43, 45, 46)*                             Bronchodilation                                                                                                      RT-qPCR, organ bath                                                                                            [@B65]
                     Alveolar macrophages                                                                                                                                                     *TAS2Rs (TAS2R3, 4, 5, 7, 8, 9, 10, 14, 19, 20, 31, 38, 39, 43, 45, 46)*                             --                                                                                                                   RT-qPCR                                                                                                        [@B64]
                     CuFi-1 cells, NuLi-1 cells                                                                                                                                               *TAS2Rs (TAS2R3, 4, 5, 8, 9, 10, 13, 14, 19, 20, 30, 31, 43, 45, 46, 50, 60)*                        --                                                                                                                   nCounter, flow cytometry                                                                                       [@B78]

The expression of *TAS2R*s in different tissues and cell lines has been examined using RT-PCR, qPCR, microarray techniques as well as RNAseq ([@B51]). Most recently, [@B78] used nCounter gene expression analysis to characterize the expression of the 29 human *TAS2Rs* in a variety of cell lines ([Table 1](#T1){ref-type="table"}). Their results showed that *TAS2R14* and *TAS2R20* were highly expressed; *TAS2R3, −4, −5, −10, −13, −19*, and *−50* were moderately expressed; *TAS2R8, −9, −21* and *−60* had low level of expression; and *TAS2R7, −16, −38, −39, −40, −41*, and *−42* were barely detectable. The nCounter technique relies on hybridization of complementary probes (spanning 100 nucleotide bases) for each gene, and hence, *TAS2R30, −31, −43, −45*, and −*46* could not be accurately discerned from one another, as they share \>92% homology. Nevertheless, this data clearly shows that some T2Rs are broadly and differentially expressed, whereas others are more restricted in their tissue distribution.

Model Systems for Expressing T2Rs and Defining Their Function {#S2}
=============================================================

In attempting to define the function of, and to identify ligands for, the T2Rs, researchers have established heterologous expression systems in human cells (e.g., HEK293 or HEK293T) ([@B119]). However, the use of these cells for understanding the underlying mechanisms and signaling pathways within cardiovascular tissues/cells has obvious limitations. Firstly, due to the insufficient cell surface targeting of T2Rs in heterologous cells ([@B23]), chimeric T2Rs encompassing the amino terminus of the rat somatostatin receptor subtype 3 are often used to improve expression and functionality ([@B15]; [@B10]). Furthermore, a chimeric G protein consisting of the Gα~16~ and 44 amino acids of gustducin attached to the carboxyl terminus is widely used in calcium mobilization assays ([@B102]; [@B184]). Gα~16~ has been coined the 'universal adaptor' due to its ability to interact with numerous GPCRs and provides a robust readout for receptor activation, including for T2Rs ([@B184]). While these artificial heterologous systems have proven useful in identifying ligands for orphan receptors ([@B119]) and interrogating the structure-function aspects of T2Rs ([@B12]), the field is now moving toward more relevant cellular models with endogenous receptors and signaling partners ([@B56]).

Studies using the aforementioned heterologous expression system have demonstrated that the majority of T2Rs form oligomers, both homodimers and heterodimers ([@B90]). However, unlike the situation for umami/sweet taste sensation (requiring dimerization of T1R1/T1R2 and T1R1/T1R3), T2R homodimers did not appear to alter the pharmacology of the receptors, nor do they have obvious influence on protein expression or membrane localization ([@B90]). In contrast, [@B84] used immuno-fluorescent microscopy to show that the co-expression of the adrenergic (ADRβ~2~) receptor with T2R14 resulted in a ∼3-fold increase in cell-surface expression of T2R14. Co-immunoprecipitation and biomolecular fluorescence complementation experiments confirmed that the increase of cell-surface expression was attributed to the formation of T2R14:ADRβ~2~ heterodimers. These complexes may be particularly important in heart where the actions of adrenergic receptors are well described. Interestingly, co-immunoprecipitation and co-internalization of ADRβ~2~:M71 OR (mouse 71 olfactory receptor) was observed in response to their specific ligands ([@B68]). These seminal observations in heterologous systems need to be confirmed and extended with endogenous models to clarify our understanding of how T2Rs function *in vivo* and to define their potential modulation of (or by) established GPCRs.

Another important issue in considering model expression systems for studying T2Rs is the requirement for appropriate accessory proteins and correct post-translational processing. It is now well-established that chemosensory receptors \[e.g., odorant ([@B117]) and pheromone ([@B104]) receptors\] rely on endogenous proteins in order to be targeted to the cell-surface. A study by [@B10] demonstrated that certain members of the receptor-transporting protein (RTP) and receptor expression enhancing protein (REEP) families enhance cell-surface localization and functionality of certain *TAS2Rs*, likely through protein--protein interactions. Furthermore, it was shown that varying combinations of these proteins are expressed endogenously within tissues (circumvallate papillae and testis) that express *TAS2R* genes. Interestingly, the human heart differentially expresses REEP 1, 2, 3, 5, and 6 across heart regions ([@B43]), suggesting that efficient cell-surface *TAS2R* expression may also be region specific. Nonetheless, these trafficking proteins do not universally promote T2R functionality, for instance T2R14 showed no increase in capacity to mobilize calcium when co-expressed with either RTP or REEP ([@B10]). There is accumulating evidence that the degree of T2R membrane insertion is dependent on the specific tissue. As T2Rs are detected in a myriad of tissues, multiple endogenous mechanisms may contribute to their appropriate expression and localization. As for many GPCRs, *N*-glycosylation of T2Rs is important for cell-surface localization--[@B150] reported that glycosylation of the second extracellular loop is essential for the recruitment (via association with the cellular chaperone calnexin) and insertion of *TAS2R*s in the cell membrane; moreover, the function of non-glycosylated *TAS2R*16 could be rescued when co-expressed with RTP3 and RTP4.

The Cardiac Gpcr Repertoire Includes T2Rs {#S3}
=========================================

The human heart expresses over 200 different GPCRs ([@B193]), some of which are critical for regulating cardiac morphology and function ([@B20]). Intriguingly, the gene transcripts for more than half of the *TAS2R* family were detected in both left ventricle and right atria ([@B53]) ranging in abundance between that observed for two classically important cardiac GPCRs -- the angiotensin II type 1 receptor and β~1~-adrenergic receptor (ADRβ~1~). It is notable that the expression of *TAS2R14* was equivalent to that of ADRβ~1~ in the left ventricle. These findings are supported by publicly available Illumina Human BodyMap 2.0 project RNA-seq dataset ([@B51]), which showed widespread *TAS2R* expression in human tissues and highest expression of *TAS2R14* in heart. It is important, however, to note that T2Rs are not uniformly detected by all techniques, with *TAS2R9*, *TAS2R39*, and *TAS2R45* not detected in the Illumina RNA-seq data set, but detected by qPCR ([@B53]). These differences could reflect individual variations, noting the body map is from one patient or the more specific nature of RNA-seq over qPCR. Interestingly, the expression of *TAS2Rs* are differentially regulated with age in mice ([@B53]), but not with sex or in heart failure ([@B54]). Furthermore, analysis of the publicly available GTEx LDACC and BioGPS Human Cell Type and Tissue Gene Expression Profiles RNA-seq datasets, highlight the expression of GNAT3 (the taste receptor specific G protein, Gα~Gustducin~) in a variety of human tissues, including the heart.

We previously investigated the factors contributing to cardiac *TAS2R* gene expression *in silico* ([@B54]). Similar to rodent *Tas2rs*, there was no evidence of enrichment for particular transcription factor binding sites in the proximal promoter regions of the human *TAS2R* genes. However, we observed that*TAS2R14* (the most abundantly expressed) had the strongest evidence of regulatory activity in its promoter region, i.e., active methylation marks overlapping with the DNase I hypersensitivity cluster. On this basis, although we cannot rule out the presence of specific transcription factors that regulate TAS2R gene expression, we reason that the proximal regulatory regions for some, but not all, *TAS2R* genes might show a basal level of transcriptional activity. This, combined with their multigene cluster expression profiles could facilitate preferential transcription of the specific *TAS2Rs* ([@B54]).

The heart is made up of 2--3 billion cardiomyocytes and yet these cells constitute less than a third of all heart tissue ([@B179]). The remaining, more than two thirds of the heart consists of smooth muscle, fibroblasts, other connective tissue cells, endothelial cells, sinoatrial cells, atrioventricular cells, Purkinje cells, pluripotent cardiac stem cells, mast cells, and other immune system-related cells ([@B179]). We have demonstrated that certain *Tas2rs* (rodent) were expressed within both cardiomyocytes and fibroblasts, as well as their downstream signaling effectors (*Gnat3*, *Plcβ2*, *Trpm5*) ([@B53]). These data suggest that specific cells within the heart may express varying populations of *TAS2R*, similar to that seen in other systems ([Table 1](#T1){ref-type="table"}). As technology advances, including single cell sequencing and proteomics ([@B185]), the topography of T2Rs within the heart will provide insight into how these receptors function within this system.

Signaling and Function of T2Rs Within the Cardiovascular System {#S4}
===============================================================

The binding of bitter ligands to T2Rs results in a conformation change in the receptor allowing it to interact with Gα~Gustducin~ and Gβ~1/3~γ~13~ ([@B72]), which then activate subsequent downstream pathways ([@B202]). Knockout (KO) studies have provided conclusive evidence supporting these signaling pathways. Mice lacking either PLCβ2 or TRPM5 exhibited diminished or ablated taste responses to bitter compounds ([@B212]). Furthermore, Gα~Gustducin~ KO mice had increased levels of cAMP, compared to the wild-type mice as well as displaying severely impaired responses to the tested compounds ([@B28]). As with Gαi-family G proteins, Gα~Gustducin~ can decrease the levels of cAMP, via the activation of phosphodiesterases, which has been observed in response to two bitter compounds, denatonium and strychnine ([@B202]). Finally, mice that were genetically modified to express novel human T2Rs demonstrated a strong aversive response to ligands that was not evident in wild-type mice ([@B128]).

With the discovery of *TAS2R* expression in cardiac tissue ([@B53]), defining the signaling transduction pathway is of particular interest, yet there is limited evidence for the presence of all the classical taste signaling components in heart. The expression of Gα~Gustducin~ has been shown in human heart tissue, and is particularly enriched in cardiomyocytes (BioGPS Human Cell Type and Tissue Gene Expression Profiles RNA-seq datasets). However, studies have not observed Gγ~13~ ([@B72]) or TRPM5 ([@B37]). TRPM4 is present within human heart tissues ([@B66]; [@B37]), however, both TRPM4 and TRMP5 are considered necessary for taste signal transduction ([@B46]). Hence, alternative signal transduction pathways that could mediate the effects of taste receptors in the cardiovascular system should be considered.

A study by [@B184] demonstrated that T2R16 could couple to a chimeric G protein consisting of the N-terminus of Gα~16~ and the last 44 amino acids of either Gα~Gustducin~, Gα~t2~or Gα~i2~. Furthermore, the expression of all three of these Gα subunits have been identified in taste receptor cells, with the frequency of Gα~i2~ being higher than that of Gα~Gustducin~ ([@B184]). [Figure 1](#F1){ref-type="fig"} shows a comparison of Gα~Gustducin~ and Gα~i2~, highlighting the highly conserved amino acid residues and the region known to interact with *TAS2R*s. Substitution of glycine^352^ for proline in Gα~Gustducin~ disrupts T2R interaction with Gα~Gustducin~, although its coupling to the Gβγ and effector molecules was preserved ([@B156]). This suggests that the extreme C terminus of both Gα~Gustducin~ and Gα~i2~ are capable of, and necessary for T2R:G protein coupling and transduction. Importantly, in human airway smooth muscle (HASM), the reported expression of Gα~i2~ expression was 100-fold higher than that of Gα~Gustducin~ and T2R14 was shown to couple to all Gα~i~ proteins, particularly Gα~i2~ ([@B85]). The use of pertussis toxin was able to abrogate the T2R mediated relaxation in HASM ([@B85]), consistent with previous studies, where T2Rs has been shown to couple with inhibitory signaling pathways ([@B139]). The actions of T2R may also include other inhibitory type processes, such as described by [@B209] in airway smooth muscle cells ([@B107]). Taken together these observations suggest that depending on the level of G protein expression and the strength of the subsequent signal, T2Rs likely couple and signal in a cell/tissue specific manner, which may include (or not) Gα~Gustducin~.

![Comparison of 2D snake representations of Gα~Gustducin~ and Gα~i2~ \[constructed via GPCRdb ([@B75])\]. Amino acids are labeled following the Ballesteros--Weinstein numbering system. Conserved amino acids are colored green. The final 44 amino acids are known to be necessary for T2R coupling and signaling ([@B184]) and are highlighted by black boxes. Arrow points to the amino acid (Glycine^352^) in Gα~Gustducin~ that disrupts T2R coupling when mutated to proline ([@B156]).](fphys-11-00431-g001){#F1}

Indeed, T2R signaling within cardiac cells might reasonably reflect those described for the respiratory system and vascular systems (summarized in [Figure 2](#F2){ref-type="fig"}). The heart is known to express specific varying combinations of Gα (including Gα~i2~), Gβγ and various signaling effector molecules ([@B43]). In a series of experiments in Langendorff-perfused mouse hearts, we observed dose-dependent negative inotropic effects in response to bitter ligands ([@B52]). A ∼40% decrease in left ventricular developed pressure and an increase in aortic pressure in response to sodium thiocynate were shown to be Gα~i~-dependent. Some alterations in cardiovascular physiology were not attributed to G proteins (not blocked by pertussis toxin and gallein), however, it was shown that rodents express GNAT3 (Gα~Gustducin~) in their cardiomyocytes ([@B53]). This further supports the premise that T2Rs can signal through various G proteins. While there is no clear consensus on the precise mechanism, there is an agreement that bitter ligands mediate contractile responses in the vasculature. One study demonstrated a transient drop in blood pressure upon intravenous injection of denatonium benzoate into rats ([@B109]). Additionally, [@B114] attributed the endothelium-independent relaxation of precontracted human pulmonary arteries to the application of bitter ligands for T2Rs (3, 4, 10, and 14). In contrast, denatonium benzoate has been shown to enhance the tone of endothelium-denuded rat aorta rings, which was attributed to specific Tas2r activation (Tas2r40, 108, 126, 135, 137, 143) via Gα~Gustducin~ ([@B103]). Whether the actions of T2Rs in cardiomyocytes have a direct effect on the force and strength of contraction of individual myocytes remains to be determined. Equally, there is a possibility that these receptors may be expressed in other cell populations, including the specific cells of the conduction system (SA node, AV node, Purkinje Fibers).

![Potential signaling pathway for T2Rs in human cardiomyocytes.](fphys-11-00431-g002){#F2}

Naturally Occurring Polymorphisms and Disease {#S5}
=============================================

GPCRs and their respective ligands have profound homeostatic and regulatory effects on the cardiovascular system. Not surprisingly, mutations and modifications of cardiovascular GPCRs, G proteins and their regulatory proteins are linked to dysfunction and disease ([@B55]). T2Rs are one of the most heterogenous and unique families of GPCRs and are now considered as a separate group of receptors ([@B41]). According to the HGNC database, there are 39 genetically diverse and highly polymorphic *TAS2R* single exon genes that encode for 29 functional T2Rs (and 10 non-coding pseudogenes) in humans ([@B40]). This is in contrast to the majority of literature that cite the existence of only 25 functional T2Rs ([@B119]; [@B106]). On average, *TAS2R* genes contain four single nucleotide polymorphisms (SNPs) of which the vast majority are non-synonyms mutations that encode amino acid substitutions ([@B86]). [Table 2](#T2){ref-type="table"} outlines all of the non-synonymous SNPs present within the population and their penetrance. These *TAS2R* genes are located on chromosomes 5, 7, and 12 ([@B3]; [@B54]), with dense clustering on chromosomes 7 and 12. The close proximity is thought to underpin the enormous variation and diversification of the T2R repertoire within humans.

###### 

List of polymorphisms in human cardiac-expressed *TAS2Rs* (penetrance \> 1% in the population) sourced from UCSC Genome Browser and NCBI SNP databases.

          **Name**      **Penetrance (\>1%)**                                 **Location**   **rs number**   **Average heterozygosity**   **Literature phenotype link**
  ------- ------------- ----------------------------------------------------- -------------- --------------- ---------------------------- --------------------------------------------------------------------------------------------------------------
  T2R3    --            --                                                    --             --              --                           
  T2R4    F7S           F (T**T**C) - 52.69%; S (T**C**C) - 47.31%            TM1            rs2233998       0.499 ± 0.025                
          V96L          V (**G**TC) - 48.29%; L (**C**TC) - 51.71%            TM2            rs2234001       0.499 ± 0.017                Sensitivity to stevioside ([@B151]), coffee consumption ([@B69])
          S171N         S (A**G**T) - 49.43%; N (A**A**T) - 50.56%            TM5            rs2234002       0.500 ± 0.006                
  T2R5    S26I          S(A**G**C) - 51.96%; I (A**T**C) - 48.03%             TM1            rs2227264       0.499 ± 0.019                Alcohol consumption ([@B27]), coffee consumption ([@B69])
  T2R9    V187A         V (G**T**G) - 40.62%; A (G**C**G) - 59.38             TM5            rs3741845       0.481 ± 0.095                Glucose homeostasis ([@B45])
          A233T         A (**G**CA) - 98.99%; T (**A**CA) - 1.01%             TM6            rs77609577      0.019 ± 0.097                
          L304F         L (**C**TT) - 99%; F (**T**TT) - 1%                   C terminal     rs3944035       0.02 ± 0.098                 
  T2R10   T156M         T (A**C**G) - 2.28%; M (A**T**G) - 97.71%             ECL2           rs597468        0.042 ± 0.139                
  T2R13   N259S         N (A**A**C) - 41.73%; S (A**G**C) - 58.27%            TM7            rs1015443       0.485 ± 0.084                Alcohol consumption ([@B44]), chronic rhinosinusitis ([@B121])
  T2R14   T86A          T (**A**CT) - 98.30%; A (**G**CT) - 1.7%              TM3            rs16925868      0.033 ± 0.125                
          L201F         L (**C**TC) - 98.47%; F (**T**TC) - 1.53%             TM5            rs35804287      0.031 ± 0.121                
  T2R16   N172K         N (AA**T**) - 97.15%; K (AA**G**) - 2.85%             TM5            rs846664        0.051 ± 0.151                Sensitivity to cyanogenic glycosides ([@B171]), alcohol dependence ([@B71]), sensitivity to salicin ([@B18])
          R222H         R (C**G**C) - 31.03%; H (C**A**C) - 68.97%            TM6            rs860170        0.429 ± 0.174                Sensitivity to salicin ([@B152])
  T2R19   V32I          V (**G**TC) - 98.75%; I (**A**TC) - 1.25%             TM1            rs56985810      0.023 ± 0.104                
          K109T         K (A**A**G) - 98.96%; T (A**C**G) - 1.04%             TM3            rs115193179     0.021 ± 0.101                
          K126Q         K (**A**AG) - 94.9%; Q (**C**AG) - 5.1%               TM4            rs12424373      0.096 ± 0.197                
          R152S         R (AG**A**) - 1.52%; S (AG**T**) - 98.48%             TM4            rs75356565      0.03 ± 0.119                 
          I225V         I (**A**TA) - 98.48%; V (**G**TA) - 1.52%             TM6            rs115299813     0.03 ± 0.119                 
          K258N         K (AA**A**) - 5.9%; N (AA**T**) - 94.1%               TM7            rs76455106      0.111 ± 0.208                
          L261F         L (**C**TC) - 93.9%; F (**T**TC) - 6.1%               TM7            rs74992161      0.114 ± 0.21                 
          C264Y         C (T**G**C) - 91.57%; Y (T**A**C) - 8.43%             TM7            rs76970958      0.154 ± 0.231                
          V267L         V (**G**TT) - 9.36%; L (**C**TT) - 90.64%             TM7            rs74772077      0.177 ± 0.239                
          G282R         G (**G**GA) - 78.67%; R (**A**GA) - 21.33%            TM7            rs72475481      0.336 ± 0.235                
          F290S         F (T**T**T) - 89.88%; S (T**C**T) - 10.12%            Helix 8        rs72475480      0.182 ± 0.241                
          W295C         W (TG**G**) - 93.77%; C (TG**T**) - 5.14%             Helix 8        rs77837442      0.122 ± 0.219                
          W295\*        W (TG**G**) - 93.77%; \* (TG**A**) - 1.09%            Helix 8        rs77837442      0.122 ± 0.219                
          M297V         M (**A**TG) - 94.4%; V (**G**TG) - 5.6%               C terminal     rs74386164      0.106 ± 0.204                
          R299C         R (**C**GC) - 53.93%; C (**T**GC) - 46.07%            C terminal     rs10772420      0.498 ± 0.035                Grapefruit juice consumption ([@B69]), sensitivity to quinine ([@B149])
          \*300W        \* (TG**A**) - 94.12%; W (TG**G**) - 5.88%            Stop codon     rs79475879      0.111 ± 0.208                
  T2R20   K79E          K (**A**AA) - 77.44%; E (**G**AA) - 22.56%            TM3            rs7135018       0.350 ± 0.229                
          V141I         V (**G**TT) - 81.6%; I (**A**TT) - 18.4%              TM4            rs79420812      0.300 ± 0.245                
          H143Q         H (CA**C**) - 58.83%; Q (CA**A**) - 41.17%            TM4            rs12226920      0.484 ± 0.087                Chronic rhinosinusitis ([@B121])
          H148N         H (**C**AC) - 58.64%; N (**A**AC) - 41.36%            TM4            rs12226919      0.485 ± 0.086                Chronic rhinosinusitis ([@B121])
          I236V         I (**A**TA) - 58.8%; L (**C**TA) - 41.2%              TM6            rs10845281      0.484 ± 0.087                
          F252S         F (T**T**T) - 58.84%; S (T**C**T) - 41.16%            ECL3           rs10845280      0.484 ± 0.087                
          R255L         R (C**G**A) - 58.84%; L (C**T**A) - 41.16%            ECL3           rs10845279      0.484 ± 0.087                
  T2R30   I199V         I (**A**TC) - 89.2%; V (**G**TC) - 10.8%              TM5            rs77777159      0.202 ± 0.245                
          Q210H         Q (CA**G**) - 1.40%; H (CA**C**) - 98.60%             ICL3           rs200082783     0.028 ± 0.144                
          S220R         S (AG**C**) - 98.1%; R (AG**A**) - 1.9%               TM6            rs201738458     0.04 ± 0.135                 
          F252L         F (TT**T**) - 56.44%; L (TT**G**) - 43.56%            ECL3           rs2599404       0.493 ± 0.06                 
  T2R31   I33T          I (A**T**T) - 80.43%; T (A**C**T) - 19.57%            TM1            rs763263807     0.315 ± 0.241                
          R35W          R (**C**GG) - 54.73%; W (**T**GG) - 45.27%            TM1            rs10845295      0.496 ± 0.042                
          L48V          L (**C**TC) - 78.68%; V (**G**TC) - 23.16%            TM2            rs760444623     0.335 ± 0.235                
          F71L          F (TT**T**) - 54.55%; L (TT**G**) - 45.45%            TM2            rs78562467      0.496 ± 0.045                
          Y76C          Y (T**A**T) - 75.88%; C (T**G**T) - 24.12%            ECL1           rs80125932      0.366 ± 0.221                
          V80L          V (**G**TA) - 53.43%; L (**T**TA) - 46.57%            TM3            rs73049074      0.498 ± 0.034                
          V87I          V (**G**TC) - 52.73%; I (**A**TC) - 47.27%            TM3            rs73049072      0.499 ± 0.027                
          L98P          L (C**T**T) - 52.29%; P (C**C**T) - 47.71%            TM3            rs73049067      0.499 ± 0.023                
          H120R         H (C**A**C) - 52.34%; R (C**G**C) - 47.66%            ICL2           rs72475488      0.499 ± 0.023                
          M132V         M (**A**TG) - 75.88%; V (**G**TG) - 24.12%            TM4            rs78152338      0.366 ± 0.221                
          Q143H         Q (CA**A**) - 88.86%; H (CA**T**) - 10.97%            TM4            rs115707514     0.206 ± 0.247                
          I147V         I (**A**TA) - 89.57%; V (**G**TA) - 10.43%            TM4            rs199736450     0.187 ± 0.242                
          K150N         K (AA**A**) - 94.91%; N (AA**T**) - 5.1%              ECL2           rs774681705     0.097 ± 0.197                
          E151Q         E (**G**AG) - 94.88%; Q (**C**AG) - 5.12%             ECL2           rs761846423     0.097 ± 0.198                
          R154W         R (**C**GG) - 94.52%; W (**T**GG) - 5.48%             ECL2           rs372544509     0.104 ± 0.203                
          L162M         L (**T**TG) - 21.98%; M (**A**TG) - 76.88%            ECL2           rs10743938      0.357 ± 0.238                
          L162V         L (TTG) - 21.98%; V (**G**TG) - 1.15%                 ECL2           rs10743938      0.357 ± 0.238                
          S170R         S (**A**GT) - 95.2%; R (**C**GT) - 4.18%              TM5            rs75346915      0.08 ± 0.183                 
          V172M         V (**G**TG) - 95.81%; M (**A**TG) - 4.19%             TM5            rs116298721     0.08 ± 0.184                 
          A177T         A (**G**CG) - 97.89%; T (**A**CG) - 2.11%             TM5            rs369562584     0.041 ± 0.138                
          Q217E         Q (**C**AA) - 80.55%; E (**G**AA) - 19.45%            ICL3           rs10845294      0.317 ± 0.241                
          A227V         A (G**C**T) - 56.34%; V (G**T**T) - 43.66%            TM6            rs10845293      0.493 ± 0.059                
          L237F         L (TT**A**) - 98.59%; F (TT**T**) - 1.41%             TM6            rs116926686     0.028 ± 0.115                
          V240I         V (**G**TT) - 57.85%; I (**A**TT) - 42.15%            TM6            rs10772423      0.489 ± 0.074                
          P276R         P (C**C**A) - 81.58%; R (C**G**A) - 18.42%            TM7            rs12318612      0.304 ± 0.244                
          W281C         W (TG**G**) - 98.49%; C (TG**T**) - 1.51%             TM7            rs139069360     0.030 ± 0.119                
          R295W         R (**C**GG) - 98.75%; W (**T**GG) - 1.25%             Helix 8        rs199894662     0.026 ± 0.111                
          V297M         V (**G**TG) - 98.7%; M (**A**TG) - 1.3%               Helix 8        rs201730548     0.026 ± 0.110                
  T2R39   --            --                                                    --             --              --                           
  T2R42   Y175F         Y (T**A**T) - 40.01%; F (T**T**T) - 59.99%            TM5            rs35969491      0.479 ± 0.100                
          *S179--*      *S (A****GA****) - 14.29%; -- (A--) - 85.71%*         TM5            *rs747949093*   *0.245 ± 0.250*              
          F196S         F (T**T**C) - 40.03%; S (T**C**C) - 59.97%            TM5            rs5020531       0.479 ± 0.100                Regulation of thyroid hormones ([@B29])
          W255G         W (**T**GG) - 83.49%; G (**G**GG) - 16.51%            TM6            rs1669413       0.272 ± 0.249                
          C265Y         C (T**G**C) - 23.68%; Y (T**A**C) - 76.32%            TM7            rs1451772       0.362 ± 0.223                
          Q292R         Q (C**A**A) - 23.7%; R (C**G**A) - 76.3%              Helix 8        rs1669412       0.362 ± 0.223                
          N310K         N (AA**C**) - 83.41%; K (AA**A**) - 16.59%            C terminal     rs1669411       0.273 ± 0.249                
          P311A         P (**C**CT) - 83.42%; A (**G**CT) - 16.58%            C terminal     rs1650017       0.273 ± 0.249                
  T2R43   W35S          W (T**G**G) - 66.15%; S (T**C**G) - 33.85%            TM1            rs68157013      0.447 ± 0.155                
          L48V          L (**C**TC) - 69.68%; V (**G**TC) - 30.32%            TM2            rs113197337     0.423 ± 0.181                
          DQILTA45-50   DQILTA - 98.39%; - 1.61%                              TM2            rs200922417     0.032 ± 0.122                
          N76Y          N (**A**AT) - 93.56%; Y (**T**AT) - 6.44%             ECL1           rs200999522     0.120 ± 0.214                
          V80L          V (**G**TA) - 97.99%; L (**T**TA) - 2.01%             TM3            rs73064968      0.039 ± 0.135                
          *I91T*        *I (A****T****C) - 96.7%; T (A****C****C) - 3.3%*     *TM3*          *rs201085601*   *0.064 ± 0.167*              
          *N92S*        *N (A****A****C) - 96.8%; S (A****G****C) - 3.2%*     *TM3*          *rs199553429*   *0.062 ± 0.165*              
          F116L         F (**T**TT) - 94.52%; L (**C**TT) - 5.48%             ICL2           rs201210705     0.104 ± 0.203                
          H120R         H (C**A**C) - 79.18%; R (C**G**C) - 20.82%            ICL2           rs201460452     0.330 ± 0.237                
          M132V         M (**A**TG) - 70.22%; V (**G**TG) - 29.78%            TM4            rs11526470      0.418 ± 0.185                
          I147V         I (**A**TA) - 60.19%; V (**G**TA) - 39.81%            TM4            rs73064966      0.479 ± 0.100                
          E151Q         E (**G**AG) - 96.38%; Q (**C**AG) - 3.62%             ECL2           rs201455884     0.070 ± 0.173                
          R154G         R (**C**GG) - 98.01%; G (**G**GG) - 1.9%              ECL2           rs200586631     0.038 ± 0.133                
          K169R         K (A**A**G) - 98.25%; R (A**G**G) - 1.75%             TM5            rs201365712     0.034 ± 0.127                
          S170R         S (**A**GT) - 97.53%; R (**C**GT) - 2.47%             TM5            rs200838689     0.048 ± 0.147                
          S170R         S (AG**T**) - 97.67%; R (AG**G**) - 2.33%             TM5            rs116243872     0.046 ± 0.145                
          F174L         F (**T**TT) - 97.11%; L (**C**TT) - 2.89%             TM5            rs113441874     0.056 ± 0.158                
          N176D         N (**A**AT) - 96.1%; D (**G**AT) - 3.9%               TM5            rs200422162     0.075 ± 0.179                
          M177T         M (A**T**G) - 95.6%; T (A**C**G) - 4.4%               TM5            rs114386807     0.084 ± 0.187                
          V182L         V (**G**TA) - 94.49%; L (**C**TA) - 5.51%             TM5            rs72477447      0.104 ± 0.203                
          L190V         L (**C**TG) - 96.64%; V (**G**TG) - 3.36%             TM5            rs200392796     0.068 ± 0.172                
          L193I         L (**C**TA) - 97.01%; I (**A**TA) - 2.99%             TM5            rs202247625     0.058 ± 0.160                
          M196L         M (**A**TG) - 97.38%; L (**C**TG) - 2.62%             TM5            rs200974913     0.051 ± 0.151                
          I199V         I (**A**TC) - 97.78%; V (**G**TC) - 2.22%             TM5            rs78179946      0.043 ± 0.141                
          C200F         C (T**G**T) - 97.91%; F (T**T**T) - 2.09%             TM5            rs144622176     0.041 ± 0.137                
          Q210H         Q (CA**G**) - 88.86%; H (CA**C**) - 10.97%            ICL3           rs201245949     0.091 ± 0.193                
          H212R         H (C**A**T) - 55.77%; R (C**G**T) - 44.23%            ICL3           rs71443637      0.491 ± 0.066                
          A227V         A (G**C**T) - 58.97%; V (G**T**T) - 41.03%            TM6            rs73064964      0.490 ± 0.07                 
          L235F         L (**C**TC) - 81.26%; F (**T**TC) - 18.74%            TM6            rs3759244       0.305 ± 0.244                
          C238R         C (**T**GT) - 94.63%; R (**C**GT) - 5.37%             TM6            rs3759245       0.102 ± 0.201                
          *G253R*       *G* (***G****GA) - 92.5%; R* (***A****GA) - 7.5%*     *ECL3*         *rs202114077*   *0.139 ± 0.224*              
          *G253E*       *G (G****G****A) - 92.6%; E (G****A****A) - 7.4%*     *ECL3*         *rs200981579*   *0.137 ± 0.223*              
          *S254N*       *S (A****G****T) - 92.9%; N (A****A****T) - 7.1%*     *ECL3*         *rs201300744*   *0.132 ± 0.220*              
          K265Q         K (**A**AA) - 97.46%; Q (**C**AA) - 2.54%             TM7            rs200291442     0.050 ± 0.149                
          R268G         R (**A**GA) - 96.89%; G (**G**GA) - 3.11%             TM7            rs202101405     0.060 ± 0.163                
          Y271C         Y (T**A**T) - 96.54%; C (T**G**T) - 3.46%             TM7            rs201618803     0.067 ± 0.170                
          P272S         P (**C**CT) - 96.53%; S (**T**CT) - 3.47%             TM7            rs200533679     0.067 ± 0.170                
          I274V         I (**A**TC) - 96.44%; V (**G**TC) - 3.56%             TM7            rs201681140     0.069 ± 0.172                
          I274T         I (A**T**C) - 96.32%; T (A**C**C) - 3.68%             TM7            rs200479139     0.071 ± 0.174                
          F290Y         F (T**T**T) - 83.84%; Y (T**A**T) - 16.16 %           Helix 8        rs111846092     0.282 ± 0.248                
          F294L         F (TT**T**) - 84.25%; L (TT**G**) - 15.75%            Helix 8        rs73064960      0.276 ± 0.249                
          W300\*        W (TG**G**) - 90.86%; \* (TG**A**) - 9.14%            C terminus     rs3759247       0.166 ± 0.236                
  T2R45   --            --                                                    --             --              --                           
  T2R46   *T16I*        *T (A****C****A) - 98.25%; I (A****T****A) - 1.75%*   *TM1*          *rs201410559*   *0.034 ± 0.127*              
          V61G          V (G**T**C) - 98.64%; G (G**G**C) - 1.36%             TM2            rs201585352     0.027 ± 0.113                
          W60--         W (**T**GG) - 98.64%; -- (-GG) - 1.36%                TM2            rs201847607     0.027 ± 0.113                
          I132M         I (AT**A**) - 98.89%; M (AT**G**) - 1.11%             TM4            rs770484573     0.022 ± 0.103                
          V141A         V (G**T**T) - 66.73%; A (G**C**T) - 33.27%            TM4            rs200936852     0.444 ± 0.158                
          I147V         I (**A**TA) - 58.3%; V (**G**TA) - 41.7%              TM4            rs72477411      0.486 ± 0.082                
          I153V         I (**A**TA) - 55.36%; V (**G**TA) - 44.64%            ECL2           rs72477410      0.494 ± 0.053                
          S170R         S (**A**GT) - 77.29%; R (**C**GT) - 22.71%            TM5            rs200171449     0.351 ± 0.229                
          N176D         N (**A**AT) - 97.86%; D (**G**AT) - 2.14%             TM5            rs766258006     0.042 ± 0.138                
          I181M         I (AT**C**) - 97.99%; M (AT**G**) - 2.01%             TM5            rs748842122     0.039 ± 0.135                
          L190V         L (**C**TG) - 98.57%; V (**G**TG) - 1.43%             TM5            rs779108518     0.028 ± 0.115                
          L228M         L (**T**TG) - 57.8%; M (**A**TG) - 42.2%              TM6            rs2708380       0.489 ± 0.074                
          W250\*        W (T**G**G) - 77.43%; \* (T**A**G) - 22.57%           TM6            rs2708381       0.350 ± 0.229                
  T2R50   C203Y         C (T**G**T) - 60.27%; Y (T**A**T) - 39.73%            TM5            rs1376251       0.479 ± 0.101                Myocardial infarction ([@B165], [@B166]; [@B183]), coronary heart disease ([@B203])

Italicized polymorphisms represent those that have less than 300 alleles detected in the sample population (\* denotes stop codon).

The importance of uncovering the primary function of T2Rs in the heart is supported by the critical role they play within the respiratory system. *TAS2R*38 is expressed in all aspects of the upper and lower respiratory tracts including sinonasal epithelial cells, bronchial epithelial cells, bronchial smooth muscle, and pulmonary vasculature smooth muscle ([@B163]; [@B65]; [@B187]; [@B40]). Application of phenylthiocarbamide (PTC) or two quorum sensing molecules (C4HSL and C12HSL) secreted by *Pseudomonas aeruginosa* were shown to increase mucociliary clearance, bronchodilation, and production of bactericidal levels nitric oxide in explanted human tissue samples and primary airway--liquid interface cultures ([@B96]). This supports the recent finding that T2Rs play a role in innate immunity, as quorum sensing molecules serve to communicate between bacterial populations, allowing them to establish themselves during infection ([@B95]). Bitter taste receptors, particularly *TAS2R*38, are a unique and diverse family of GPCRs due to the number of their naturally occurring genetic variants ([@B86]). Compared to the functional (PAV) haplotype, individuals with the non-functional (AVI) haplotype were shown to be more susceptible to respiratory infections as the receptor was unable to detect the compounds and respond appropriately ([@B96]). A similar result was seen with regard to oral innate immunity ([@B62]). *TAS2R*38 PAV/PAV mRNA was upregulated ∼4.3-fold in response to *Streptococcus mutans* bacteria (over the unstimulated control) whereas the AVI/AVI was only ∼1.2-fold. Furthermore, the level of hBD-2 (antimicrobial peptide) induced was highest in those with the PAV/PAV genotype ([@B62]). On this basis, the authors concluded that a person's T2R38 genotype determines oral innate immunity.

Natural polymorphisms are no longer thought only to account for differences in oral bitter taste perception ([@B154]). It is now recognized that these polymorphisms also influence other important aspects of our physiology including alcohol dependence, eating behavior, longevity, glucose homeostasis and regulation of thyroid hormones ([@B45]; [@B69]; [@B17]; [@B29]). There are 132 naturally occurring non-synonymous polymorphisms for cardiac-expressed T2Rs and it is clear that the majority of these remain uncharacterized ([Table 3](#T3){ref-type="table"}). One polymorphism that is of particular interest is T2R50-rs1376251, as debate remains in the literature over its potential association with myocardial infarction and coronary heart disease ([@B166]; [@B177]; [@B203]; [@B88]; [@B76]; [@B183]). There are also polymorphisms outside of the taste receptor coding region, or those that result in synonymous mutations that have been associated with changes in physiology. Of note, T2R14 rs3741843 has been associated with decreased sperm motility ([@B61]). Individuals that were homozygous carriers for the (G) allele, encoding arginine (R -- AG[G]{.ul}), showed a decreased sperm progressive motility compared to heterozygotes and homozygotes for the (A) allele, which encodes arginine (R -- AG[A]{.ul}). The authors rationalized using *in silico* analysis that T2R14 regulates the expression of T2R43. Furthermore, an upstream mutation of *TAS2R*3 rs11763979 can regulate the expression of WEE2 antisense RNA one (WEE2-AS1), which increases the expression of WEE2 within the testis. WEE2 is a protein tyrosine kinase involved in the regulation of cell cycle progression ([@B130]). Overexpression of WEE2 in the testis was hypothesized to increase the number of abnormal sperm cells ([@B61]). Despite recent progress, it is unclear the full extent to which polymorphisms can influence T2R physiology, although it is clear investigation into their effects is warranted.

###### 

List of ligands known to activate cardiac specific T2Rs and their classification, number of T2Rs activated \[bold indicates the receptor corresponding to the lowest threshold (TC) or effective concentration (EC50) *in vitro* concentration\], reported effects in the cardiovascular system and corresponding dose/serum (\* = based on 5.5 L of blood in human body, or without First Pass Effect of liver).

                                               **Classification**                        **Activates T2R** ([@B77])                          ***In vitro* (μM) - TC/EC50** [@B77]   **Reported effects on cardiovascular system**                                                                                                                                                                                                                                                **Reported doses**                                         **Reported or equivalent serum (μM)**
  -------------------------------------------- ----------------------------------------- --------------------------------------------------- -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- -----------------------------------------
  **Bitter compounds in food**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Absinthin                                    Sesquiterpene lactone                     10, 14, **30**, 46                                  0.4 ± 0.06 (EC50)                      --                                                                                                                                                                                                                                                                                           --                                                         --
  Acesulfame K                                 Artificial sweetener                      **31**, 43                                          2500 ± 10 (EC50)                       --                                                                                                                                                                                                                                                                                           --                                                         --
  Apigenin                                     Flavonoid                                 **14**, 39                                          20.5 (EC50)                            --                                                                                                                                                                                                                                                                                           --                                                         --
  Amarogentin                                  Secoiridoid glycoside                     30, 39, 43, **46**, 50                              65 ± 16 (EC50)                         --                                                                                                                                                                                                                                                                                           --                                                         --
  Andrographolide                              Diterpenoid lactone                       30, **46**, 50                                      13 ± 2.17 (EC50)                       Shortened AP duration and reduced maximum upstroke (rabbits) ([@B208])                                                                                                                                                                                                                       --                                                         --
  Aristolochic acid                            Carcinogen                                14, 31, **43**                                      0.081 ± 0.0008 (EC50)                  Valvular heart disease - aortic sufficiency ([@B188])                                                                                                                                                                                                                                        --                                                         --
  Caffeine                                     Stimulant                                 10, 14, 43, 46                                      300 (TC)                               Tachycardia, arrhythmia ([@B21])                                                                                                                                                                                                                                                             80--100 mg/L                                               \>400
  Datiscetin                                   Flavonoid                                 **14**, 39                                          10 (EC50)                              --                                                                                                                                                                                                                                                                                           --                                                         --
  (-)-Epicatechin                              Antioxidant                               4, 5, **39**                                        417.7 (EC50)                           Promotes vasodilation (increase NO and decrease endothelin-1) ([@B161]; [@B105]; [@B113])                                                                                                                                                                                                    --                                                         --
  (-)-Epicatechin gallate (Ecg)                Flavonoid                                 **14**, 39                                          70 (EC50)                              --                                                                                                                                                                                                                                                                                           --                                                         --
  (-)-Epigallocatechin gallate (EGCg)          Flavonoid                                 **14**, 39                                          34 (EC50)                              Reduction of diastolic BP ([@B13])                                                                                                                                                                                                                                                           800 mg                                                     ∼300 (without First Pass Effect)\*
  Falcarindiol                                 Antitumorigenic                           14                                                  100 (TC)                               --                                                                                                                                                                                                                                                                                           --                                                         --
  Genistein                                    Phytoestrogen                             **14**, 39                                          28.9 (EC50)                            --                                                                                                                                                                                                                                                                                           --                                                         --
  Histidine                                    α-Amino acid                              39                                                  430 (TC)                               Arrhythmia prevention, inotropic support ([@B22]; [@B176])                                                                                                                                                                                                                                   198 mM                                                     8000--21000\*
  Humulone isomers                             Alpha acid                                14                                                  0.01 (TC)                              Inhibit VEGF mediated angiogenesis and endothelial proliferation (mouse) ([@B167])                                                                                                                                                                                                           --                                                         100
  Naringenin                                   Flavonoid                                 14, **39**                                          32.9 (EC50)                            --                                                                                                                                                                                                                                                                                           --                                                         --
  Procyanidin                                  Flavonoid                                 5                                                   35.6 ± 0.7 (EC50)                      Improved hemodynamic parameters and collagen content (rats) ([@B116])                                                                                                                                                                                                                        6500 mg (65 kg human, 100 mg/kg)                           ∼2000 (without First Pass Effect)\*
  Quercetin                                    Flavonoid                                 14                                                  1 (TC)                                 Reduction in BP ([@B162])                                                                                                                                                                                                                                                                    \>500 mg                                                   ∼300 (without First Pass Effect)\*
  Sodium benzoate                              Preservative                              **14**, 16                                          300 (TC)                               Caffeine alkaloid - combined with caffeine ([@B207])                                                                                                                                                                                                                                         --                                                         --
  Sinigrin                                     Glucosinolate                             16                                                  100 (TC)                               --                                                                                                                                                                                                                                                                                           --                                                         --
  Thiamine                                     Vitamin B1                                39                                                  1000 (TC)                              Deficiency results in wet beriberi ([@B99])                                                                                                                                                                                                                                                  --                                                         --
  Thujone, (-)-α                               Stimulant                                 10, **14**                                          15 (EC50)                              Arrhythmia, hypotension, vasodilation (rats) ([@B144])                                                                                                                                                                                                                                       12480 mg (65 kg human, 192 mg/kg)                          15000 (without First Pass Effect)\*
  **Chemicals/drugs**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Allylthiourea                                Nitrification inhibitor                   50                                                  720 ± 150 (EC50)                       --                                                                                                                                                                                                                                                                                           --                                                         --
  Atropine                                     Muscarinic antagonist                     10, 46                                              100 (TC)                               Tachycardia, arrhythmogenic (mice) ([@B142])                                                                                                                                                                                                                                                 --                                                         --
  Azathioprine                                 Immuno- suppressant                       4, 10, **14**, 46                                   100 (TC)                               Atrial fibrillation, hypotension, tachycardia, cardiogenic shock ([@B42]; [@B14])                                                                                                                                                                                                            50 mg/day (2 weeks before hospital admission)              32 (without First Pass Effect)\*
  Azithromycin                                 Antibiotic                                4                                                   74.45 ± 12.3(EC50)                     Ventricular tachycardia, prolongation of QT interval, torsades de pointes ([@B157]; [@B182])                                                                                                                                                                                                 500 mg/day i.v.                                            ∼115\*
  4,4-Bipyridine                               Bipyridine                                **10**, 14, 16                                      3680 ± 60 (EC50)                       Other bipyridines used in heart disease and cardiac arrhythmias                                                                                                                                                                                                                              --                                                         --
  Benzamide                                    Benzamides                                14                                                  300 (TC)                               Substituted benzamides linked to hypotension, prolongation of QT interval, ventricular arrhythmias                                                                                                                                                                                           --                                                         --
  Carisoprodol                                 Muscle relaxer                            14                                                  100 (TC)                               Tachycardia, hypotension, heart palpitations ([@B153]; [@B191])                                                                                                                                                                                                                              71 mg/L                                                    \>250
  Chloroquine                                  Antimalarial                              **3**, 10, 39                                       172 ± 29 (EC50)                        Cardiomyopathy, hypertrophy, ventricular arrhythmias: ST-segment depression, T wave inversion and QT interval prolongation, relaxation ([@B47]; [@B172]; [@B180])                                                                                                                            300 mg                                                     \>900 (without First Pass Effect)\*
  Chlorpheniramine                             Antihistamine                             4, **10**, 14, 39, 46                               10 (TC)                                QT interval prolongation, torsades de pointes tachycardia ([@B131])                                                                                                                                                                                                                          2.5 mg (2.5 mg, two capsules three time a day)             ∼10 (without First Pass Effect)\*
  Chloramphenicol                              Antibiotic                                10, 39, 41, 43, **46**                              10 (TC)                                Gray Baby Syndrome - hypotension, arrhythmias; cardiovascular collapse ([@B175]; [@B11]; [@B174])                                                                                                                                                                                            313 mg/L                                                   \>950
  Clonixin                                     NSAID                                     14                                                  2 (TC)                                 Cardiodepression and hypotension (rats) ([@B16]; [@B125])                                                                                                                                                                                                                                    7800 mg (65 kg human, 120 mg/kg - lethal dose i.v. rats)   \>5000 (without First Pass Effect)\*
  Chlorhexidine                                Antiseptic                                14                                                  0.1 (TC)                               Hemodynamic instability and vasodilatory shock ([@B67]; [@B215])                                                                                                                                                                                                                             Chlorhexidine-coated central venous catheter               --
  Colchicine                                   Antigout                                  4, 39, 46                                           1025 ± 121 (EC50)                      Decreased rates of atrial fibrillation, pericarditis and atherosclerotic vascular disease; cardiac arrhythmias and cardiovascular collapse ([@B111]; [@B140]; [@B178])                                                                                                                       1 mg/day                                                   0.45 (without First Pass Effect)\*
  Cycloheximide                                Eukaryote protein synthesis inhibitor     10                                                  100 (TC)                               --                                                                                                                                                                                                                                                                                           --                                                         --
  Cromolyn                                     Mast cell stabilizer                      **20**, 43                                          42 ± 25 (EC50)                         Attenuates adverse LV remodeling and dysfunction in myocarditis, restored cardiac contractile dysfunction (rats) ([@B159]; [@B123])                                                                                                                                                          1625 mg (65 kg human, 25 mg/kg i.p. rats)                  630 (without First Pass Effect)\*
  Dapsone                                      Antibiotic                                4, 10                                               100 (TC)                               Myocardial injury, shock, ventricular dysrhythmia, cardiac arrest. Hypertension ([@B82]) ([@B93]; [@B216])                                                                                                                                                                                   300 mg--3 g                                                219--2190 (without First Pass Effect)\*
  Denatonium benzoate                          Deterring agent                           4, 10, 13, **30**, 39, 43, 46                       0.27 ± 0.06 (EC50)                     Vasodilation (rats) ([@B109])                                                                                                                                                                                                                                                                1 μM i.v. in rats                                          --
  Dextromethorphan                             Sedative                                  10                                                  10 (TC)                                QT interval prolongation, torsades de pointes tachycardia, hypertension ([@B83]; [@B201]; [@B187]; [@B26])                                                                                                                                                                                   1920 mg (27 mg/kg)                                         \>1000 (without First Pass Effect)\*
  Diphenhydramine                              Antihistamine                             14                                                  30 (TC)                                QT interval prolongation, ventricular tachycardia, hemodynamic collapse, cardiac arrest, junctional rhythm, complete right bundle branch block, hypotension ([@B206]; [@B1]; [@B91]; [@B132])                                                                                                18.7 mg/L                                                  73
  Diphenidol                                   Antiemetic                                4, 10, 13, 14, 16, 20, 30, **31**, 39, 43, 46       3 (TC)                                 Contraction band necrosis (post mortem), hypotension, arrhythmia, including QT interval prolongation, T wave change, U wave appearance, AV block, bundle branch block, ventricular premature contraction, ventricular tachycardia and ventricular fibrillation ([@B195]; [@B204]; [@B210])   45 mg/L                                                    145
  Erythromycin                                 Antibiotic                                10                                                  300 (TC)                               QT interval prolongation, torsades de pointes tachycardia, 68% increased of hospital-acquired cardiac events (arrhythmia, heart failure, myocardial ischemia) ([@B63]; [@B147])                                                                                                              1300 mg (65 kg human, 15--20 mg/kg i.v. every 6 h)         \>300\*
  Ethylhydrocupreine                           Antibiotic                                14                                                  10 (TC)                                --                                                                                                                                                                                                                                                                                           --                                                         --
  Famotidine                                   Antacid                                   10, 31                                              300 (TC)                               Cardiac arrest, third degree heart block, decreased stroke volume and cardiac output ([@B87]; [@B160]; [@B94])                                                                                                                                                                               2x 20 mg i.v. dose                                         \>20\*
  Flufenamic acid                              NSAID                                     14                                                  0.137 ± 0.017 (EC50)                   Hypertension and congestive heart failure ([@B124])                                                                                                                                                                                                                                          600 mg                                                     \>350 (without First Pass Effect)\*
  Haloperidol                                  Antipsychotic                             10                                                  30 (TC)                                Prolongation of QT interval, torsades de pointes, sudden cardiac death ([@B120]; [@B49]; [@B190])                                                                                                                                                                                            2--1540 mg I.v. dose (cumulative)                          0.9--740\*
  Hydrocortisone                               Medication form of cortisol               46                                                  30 (TC)                                                                                                                                                                                                                                                                                                                                                                                        
  Levofloxacin                                 Antibiotic                                4, **14**, 20                                       74.69 ± 20.5(EC50)                     Ventricular tachycardia, prolongation of QT interval, torsades de pointes ([@B9]; [@B108]; [@B135])                                                                                                                                                                                          500 mg/day i.v.                                            ∼250\*
  Ofloxacin                                    Antibiotic                                9                                                   200 (EC50)                             --                                                                                                                                                                                                                                                                                           --                                                         --
  Orphenadrine                                 Anticholinergic/antihistamine             46                                                  30 (TC)                                Prolongation of QT interval, torsades de pointes, bradycardia, asystole ([@B112]; [@B35]; [@B110])                                                                                                                                                                                           16.2 mg/L                                                  \>60
  Methoxsalen/Xanthotoxin                      Small molecule - inhibits DNA synthesis   10, **14**, 20                                      10                                     --                                                                                                                                                                                                                                                                                           --                                                         --
  Noscapine                                    Antitussive                               14                                                  10 (TC)                                Hypotension, relaxation ([@B196]; [@B114])                                                                                                                                                                                                                                                   --                                                         100
  Parthenolide                                 Antispasmodic                             10, 31, **46**                                      1 (TC)                                 --                                                                                                                                                                                                                                                                                           --                                                         --
  Pentagalloyl glucose (PGG)                   Antitumorigenic                           5, **39**                                           6.6 (EC50)                             Modulates perivascular inflammation and prevents vascular dysfunction in Ang II-induced hypertension (mice) ([@B122])                                                                                                                                                                        650 mg (65 kg human, 10 mg/kg i.p.)                        ∼125 (without First Pass Effect)\*
  1, 10-Phenanthroline                         Antimicrobial                             5                                                   100 (TC)                               --                                                                                                                                                                                                                                                                                           --                                                         --
  Picrotoxinin                                 Stimulant                                 10, 14, 30, **46**                                  18 (EC50)                              AV block, ventricular premature contraction and/or ventricular tachycardia (rats) ([@B98], [@B97]; [@B100])                                                                                                                                                                                  1300 mg (65 kg human, 20 mg/kg i.v.)                       ∼12\*
  Pirenzepine                                  Anticholinergic                           9                                                   1800 (EC50)                            Increased heart rate turbulence, augmented baroreceptor reflex sensitivity ([@B141]; [@B192])                                                                                                                                                                                                50 mg/day                                                  ∼25 (without First Pass Effect)\*
  Procainamide                                 Antiarrhythmic                            9                                                   2800 (EC50)                            Decrease contractility, hypertension, cardiovascular depression and collapse, prolonged PR/QT intervals and QRS complex, AV block, asystole, bundle branch block, ventricular premature contraction, ventricular tachycardia and ventricular fibrillation ([@B143]; [@B137]; [@B138])        1300 mg (65 kg human, 10 mg/kg/20 min (i.v.)               ∼1000\*
  Quinine                                      Antimalarial                              4, **10**, **14**, **31**, **39**, **43**, **46**   10 (TC)                                Hypotension, prolonged PR/QT intervals and QRS complex, bundle branch block, ventricular premature contraction, ventricular tachycardia and ventricular fibrillation ([@B34]; [@B137]; [@B138])                                                                                              10 mg/L                                                    ∼31
  Salicin                                      Anti-inflammatory                         16                                                  1400 ± 200 (EC50)                      --                                                                                                                                                                                                                                                                                           --                                                         --
  Salicylic acid                               Derivative of aspirin                     14                                                  1000 (TC)                              Supraventricular tachycardia, prolonged asystole, atrial fibrillation ([@B129]; [@B74])                                                                                                                                                                                                      0.49--1.1 mg/mL                                            ∼3500--8000
  Strychnine                                   Pesticide                                 10, **46**                                          0.43 ± 0.02 (EC50)                     Cardiac arrest, bradycardia, ECG changes ([@B70]; [@B199]; [@B146])                                                                                                                                                                                                                          3.8 mg/L                                                   ∼11
  2-Thiouracil                                 Antithyroid                               4, **14**, 46                                       100 ± 10 (EC50)                        --                                                                                                                                                                                                                                                                                           --                                                         --
  Tobramycin                                   Antibiotic                                14, **20**                                          50.97 ± 19.37 (EC50)                   Cardiodepression, hypotension, decreased CO, ventricular contractile force (dogs) ([@B2])                                                                                                                                                                                                    1300 mg (65 kg human, 20 mg/kg i.v.)                       ∼500\*
  Yohimbine                                    Erectile dysfunction                      4, 10, 46                                           300 (TC)                               Promote cardiac noradrenaline release (mice) ([@B194])                                                                                                                                                                                                                                       260 mg (65 kg human, 4 mg/kg)                              \>130 (without First Pass Effect)\*
  **Endogenous factors**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Alanine                                      α-Amino acid                              39                                                  580 ± 10 (EC50)                        --                                                                                                                                                                                                                                                                                           --                                                         --
  Androsterone                                 Steroid hormone                           46                                                  1 (TC)                                 --                                                                                                                                                                                                                                                                                           --                                                         --
  Pantothenic acid                             Vitamin B5                                14, 31, 43                                          1000 (TC)                              --                                                                                                                                                                                                                                                                                           --                                                         --
  Progesterone                                 Steroid hormone                           46                                                  3 (TC)                                 QTc shortening (double autonomic blockade, atropine and propranolol) - opposite effect of estradiol ([@B6]; [@B205]; [@B158]; [@B7])                                                                                                                                                         6500 μg (65 kg human, 100 μg/kg i.v.)                      \>3.5\*
  Taurocholic acid                             Primary bile acid                         4                                                   300 (TC)                               Afterdepolarizations, atrial fibrillation, prolongation of contractile refractory period ([@B38]; [@B148])                                                                                                                                                                                   --                                                         300--1000
  **Bacterial toxins/metabolic by-products**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Equol                                        Nonsteroid estrogen                       14, 39                                              100                                    --                                                                                                                                                                                                                                                                                           --                                                         --
  4-Hydroxy-2-heptylquinolone (HHQ)            *Pseudomonas aeruginosa* quinolone        14                                                  100                                    --                                                                                                                                                                                                                                                                                           --                                                         --
  Homoserine lactone, *N*-butyryl-L*-*         Bacterial quorum sensing                  14                                                  50                                     --                                                                                                                                                                                                                                                                                           --                                                         --
  Homoserine lactone, *N*-hexanoyl-L-          Bacterial quorum sensing                  10                                                  2400 (TC)                              --                                                                                                                                                                                                                                                                                           --                                                         --
  Homoserine lactone, *N*-octanoyl-L-          Bacterial quorum sensing                  4, **14**, 20                                       20 ± 10 (EC50)                         --                                                                                                                                                                                                                                                                                           --                                                         --
  Homoserine lactone, *N*-3-oxooctanoyl-L-     Bacterial quorum sensing                  **4**, 10, 14, 20                                   41 ± 13 (EC50)                         Bradycardia (rats) ([@B60])                                                                                                                                                                                                                                                                  650 mg (65 kg human, 10 mg/kg i.v.)                        \>450\*
  *Pseudomonas* quinolone signal (PQS)         *Pseudomonas aeruginosa* quinolone        **4**, 16, 39                                       100                                    --                                                                                                                                                                                                                                                                                           --                                                         150 ([@B126])

Potential Cardiovascular T2R Ligands {#S6}
====================================

T2Rs are unique as they lack most of the conserved motifs of the class A GPCR family ([@B92]). The intracellular loops -- regions necessary for signal transduction and feedback modulation ([@B127]), were shown to be more conserved across T2Rs than the extracellular loops that are generally implicated in receptor binding ([@B118]). Using T2R14 as an example, [@B133] demonstrated that *in vitro* mutagenesis of 19 receptor mutants (all within the binding pocket) retained the ability to bind at least one of the 7 tested agonists while some improved signaling compared to the wild type. These results are consistent with previous literature that ligands bind within the transmembrane and extracellular domain regions ([@B12]; [@B186]). Interestingly, of the highly expressed cardiac T2Rs, T2R10, T2R14, and T2R46 were shown to bind a wide array of ligands, which is considered disproportional in comparison to the others ([@B119]). Over 75% of the list of ligands in [Table 3](#T3){ref-type="table"} were shown to activate these three broadly tuned T2Rs.

Universally, researchers have used chemicals that 'taste bitter' to test for potential ligands. However, if heart tissue expresses over half of the T2Rs family, a major question arises - what is the source of ligands for these T2Rs within the cardiovascular system? We would argue there are four major sources: (1) bitter compounds in food, (2) endogenously produced factors, (3) bacterial metabolic by-products and toxins and (4) chemicals/drugs (outlined in [Table 3](#T3){ref-type="table"}).

The post-prandial concentration of bitter compounds in the blood increases. One perhaps common example of this is caffeine, which reportedly modulates calcium signaling via interaction with the ryanodine receptor ([@B89]). Interestingly, caffeine also activates T2R10, -14, and -46 ([@B119]; [@B21]) at concentrations that occur in blood post-prandially and which are equivalent to levels that modulate the ryanodine receptor ([@B89]). In the gut, caffeine activation of T2R has been linked to gastric secretion ([@B101]). Caffeine may also act as a stimulate for the central nervous system via the antagonism of adenosine receptors ([@B50]). Hence in considering the homeostatic consequence of bitter compounds (such as caffeine) one must also accept that at high concentrations they are interacting with multiple receptor systems. We would anticipate that many bitter compounds in food would have actions on both T2Rs and other targets.

Another interesting possibility is that the body produces endogenous factors that could activate T2Rs. Currently, alanine, pantothenic acid (vitamin B5), steroids (androsterone and progesterone) and taurocholic acid (primary bile acid) have all been identified as ligands for specific receptors ([@B80]; [@B106]). Potentially, the cardiotonic steroids may be ligands for cardiac-expressed T2Rs, although ouabain has already been shown not to be an agonist *in vitro* ([@B119]), despite being able to augment calcium transients in arterial smooth muscle ([@B5]). The other members of this family could also be investigated as potential ligands for cardiac T2Rs. Whether hormones/factors produced by other tissues, or indeed paracrine factors released from cardiac cells, can bind and activate cardiac T2Rs remains to be determined, but is an area of intense interest.

A more provocative idea is that colonizing bacteria, in complex organisms, could produce bitter compounds, including metabolic by-products and other signaling molecules that alter our physiology via T2Rs. A recent study showed commensal bacteria are enable to synthesize GPCR ligands that mimic human signaling molecules ([@B31]). Broad screening for bacterial metabolites that activate GPCRs ([@B25]; [@B33]) have identified numerous candidates, but unfortunately these screens have not included the taste receptors. Interestingly, an olfactory receptor (Olfr78) has been reported to respond to short chain fatty acids produced by gut bacteria ([@B145]). Olfr78 KO mice had elevated blood pressure when treated with antibiotics. As for the T2Rs, T2R38 although its expression is low in the heart, was shown to be broadly tuned for seven bacterial metabolites ([@B189]). It is also worth noting that during infections bacterial toxins could be 'bitter' and interact with T2Rs once they reached a certain concentration in the blood. One example is quorum sensing molecules - when they reach a certain concentration, bacteria produce a biofilm in order to evade and survive the host immune defense system ([@B36]). Therefore, it is plausible that T2Rs may alter cardiovascular physiology in response to systemic infections such as sepsis where dramatic cardiovascular changes are observed, e.g., decreased myocardial contractility, vasodilation, endothelial injury and increased heart rate ([@B168]).

Finally, it is important to address the possibility that off-target activation of T2Rs may play a role beyond normal physiology and mediate unexpected responses to therapeutic drugs, many of which are bitter. Indeed, the possibility that T2Rs act as the mediators of off-target drug effects due to the prevalence of their expression throughout the body has been discussed previously ([@B30]). There are numerous drugs/chemicals that have specific, detrimental cardiovascular effects and, moreover, these chemicals have been shown to activate specific T2Rs at concentrations to those that elicit these adverse effects.

Future Directions {#S7}
=================

The continuous, proper functioning of the heart is fundamental to life. The discovery of T2Rs expressed in cardiac cells predicts important (but yet to be appreciated) roles in heart physiology, as well as its response to external challenges (e.g., diet, metabolic changes, infections, and drugs). Research and knowledge regarding the physiology of T2Rs within the human heart is challenging, primarily due to the constraints of readily acquiring suitable human heart tissue samples. Furthermore, the lack of homology between rodent Tas2rs and human T2Rs ([@B53]), limits the utility of gene modified animal models to directly inform human physiology. Additionally, the 29 T2Rs (and their many variants) have been historically difficult to heterologously express on the cell membrane of model cells, and this has impeded further investigation of their signaling properties.

It is important to note, that researchers have ectopically expressed human T2Rs in mice and this has provided strong confirmation that a given ligand (tastants) can activate a specific human T2R ([@B128]). Perhaps future experiments might extend this approach to develop transgenic mice expressing human T2Rs in a cell-specific context. Stimulation of these receptors with ligands that selectively bind and activate only human T2Rs could provide important insights into the physiological role(s) of T2Rs in human tissues.

Another critical objective will be to develop appropriate cardiac models that express endogenous receptors and recapitulate cardiac physiology. One major advance in cardiovascular research has been the development of induced pluripotent stem cell-derived human cardiomyocytes ([@B73]; [@B170]) and human cardiac organoids ([@B134]). These models will offer the unique opportunity to modulate T2R expression in cardiomyocytes and to thereby investigate bitter ligand-driven changes in cardiac gene transcription, as well as to define alterations in cardiac contractility and function.

Finally, the ultimate goal will be to attribute T2R-mediated expression, activation and signaling to definitive changes in human cardiovascular function *in vivo*. In order for this to succeed, the following challenges need to be resolved - the promiscuity of bitter receptor--ligand interactions, the elucidation of tissue-specific T2R signaling, as well as the lack of definitive research tools (e.g., selective antibodies to T2Rs and specific receptor antagonists). We anticipate that studies focused on examining the functionality (or lack thereof) for the various highly penetrant, cardiac-expressed T2R polymorphisms may provide the means for unambiguously attributing T2R activation to a specific physiological outcome. Analogous to the advances made with non-functional T2R38 variants (T2R38AVI) in the lung, we predict that non-functional, cardiac-expressed T2Rs can be identified and these will prove to be critical in providing the necessary controls for investigating explanted cardiac tissues.
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